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Abstract 
 
Background: High-dose methotrexate (HDMTX) is considered standard of care for 
patients with newly diagnosed primary central nervous system lymphoma (PCNSL). 
The role of whole brain radiotherapy (WBRT) has remained controversial: delayed 
neurotoxicity limits its acceptance as a standard of care. The aim of the G-PCNSL-
SG-1 trial was to test the hypothesis that the omission of WBRT from first-line 
treatment based on HDMTX does not compromise overall survival (OS). 
Methods: The G-PCNSL-SG-1 trial (www.clinicaltrials.gov NCT00153530) 
randomised (fax randomisation, based on computer-generated random list) 
immunocompetent patients with newly diagnosed PCNSL to chemotherapy followed 
by WBRT or chemotherapy alone. Patients were stratified according to age, < 60 
versus > 60 years, and institution (Berlin versus Tübingen versus all other sites). All 
patients were to receive 6 cycles HDMTX from 1999-2007 and HDMTX plus 
ifosfamide thereafter. Patients achieving a complete response (CR) received 
consolidating WBRT (45 Gy, 1.5 Gy fractions) (arm A1) or no further treatment (A2). 
Patients without CR received WBRT (B1) or HD-cytarabine (HD-Ara-C) (B2). The 
primary endpoint was overall survival (OS). We hypothesized that the omission of 
WBRT from first-line treatment does not compromise OS, using a non-inferiority 
design with a margin of 0.9. The per protocol population was used in the primary 
analysis. 
Findings: 551 patients (median age 63 years) entered the study; of 526 who fulfilled 
the eligibility criteria, 66 died during HDMTX-based chemotherapy, 49 dropped out, 
and 411 entered the post-HDMTX phase; 318 were treated per protocol (PP 
 4
population). For this PP population, median OS was 32.4 months (95% CI 25.8-39) 
in the chemotherapy+WBRT arms (A1+B1, n=154) and 37.1 months (95% CI 27.4-
46.7) in the chemotherapy alone arms (A2+B2, n=164) (p=0.7, HR 1.06, 95%CI 0.8-
1.4). Thus the primary hypothesis was not proven. Median progression-free survival 
(PFS) was 18.3 (95% CI 11.6-25) and 11.9 months (95% CI 7.3-16.5, p=0.13). 
Treatment-related neurotoxicity in patients with a sustained CR was more common 
in the WBRT arm (22/45 = 48.9% by clinical assessment, 35/49 = 71.4% by 
neuroradiology) than in the chemotherapy alone arm (9/34 = 26.5% by clinical 
assessment, 16/35 = 45.7% by neuroradiology). 
Interpretation: No significant difference in OS was found when WBRT was omitted 
from primary therapy in patients with newly diagnosed PCNSL. The PFS benefit 
afforded by WBRT has to be weighed against the probably increased risk of 
neurotoxicity in long-term survivors.  
 
Funding: German Cancer Aid 
 
Key words: primary central nervous system lymphoma, chemotherapy, whole brain 
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Introduction 
 
PCNSL is a rare brain tumor with an annual incidence of 0.5/100,000 and a median 
age at diagnosis of 60-65 years (www.cbtrus.org). The incidence of PCNSL is 
supposed to be rising in immunocompetent individuals whereas it seems to be 
decreasing in HIV-positive patients. The median survival is in the range of 10-20 
months. Survival at 5 years is below 20-30%.1-6 
Standards of care have not been well defined yet. Surgical measures beyond a 
stereotactic biopsy to confirm the diagnosis are not recommended. WBRT induces 
complete remissions (CR) defined by neuroimaging in up to 60% of the patients, but 
their durations are usually short, and the median survival is in the range of only 12-
18 months.7 HDMTX administered at doses above 3.5 g/m2 in 2-3 weeks intervals is 
the most active drug. The combination of HDMTX-based chemotherapy and WBRT, 
with or without intrathecal chemotherapy, produced both high response rates and 
extended survival up to 30-60 months in phase II studies,8-11 but was associated with 
intolerable long-term neurotoxicity especially in the elderly.12-13 Accordingly, various 
strategies maintaining treatment efficacy, but reducing toxicity, were explored, 
including the use of HDMTX alone.14-16 However, the German NOA-03 trial did not 
confirm adequate response rates and survival times with HDMTX alone as the first-
line treatment for PCNSL.17-18 The response rate increased when HD-Ara-C was 
added to HDMTX as part of the first-line chemotherapy.19 The role of WBRT added 
to HDMTX in the primary treatment of PCNSL has been identified as the most 
important question to address.20 Accordingly, the G-PCNSL-SG already in 1999 
designed a randomised trial (www.clinicaltrials.gov NCT00153530) to test the 
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hypothesis that primary HDMTX-based chemotherapy alone was not inferior to 
primary chemotherapy followed by WBRT for patients with newly diagnosed PCNSL 
(Figure 1). 
 
 
Patients and Methods 
 
Study design 
The inclusion criteria were: PCNSL confirmed by histology or by cytology or 
immunocytochemistry from the cerebrospinal fluid (CSF), no prior cytostatic 
treatment, no evidence of extra-CNS involvement, written informed consent, age >18 
years, life expectancy > 2 months, neutrophil count >1500/l, platelets >100 000/l, 
normal total bilirubin, transaminases < 3x the normal value and a creatinine 
clearance >50 ml/min. Major exclusion criteria were: concomitant 
immunosuppression including positive HIV serology, active infection, a Karnofsky 
performance score (KPS) < 50% for reasons not related to PCNSL and <30% for 
PCNSL-related reasons, concomitant malignancy, pregnancy, breast feeding, no 
effective contraception in women with child-bearing potential, and treatment with 
non-steroidal anti-inflammatory drugs, sulfonamides or penicillins within 1 week prior 
to HDMTX. 
Staging included physical examination, mini-mental status examination (MMSE), 
biochemical serum profile, HIV, hepatitis B and C serological assessment, CT scans 
of chest and abdomen, brain MRI (CT when MRI was not available or possible), 
bone marrow biopsy, ophthalmological assessment, and CSF examination. Central 
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pathology review was recommended but not mandatory for enrolment. The patients 
were stratified according to age, < 60 versus > 60 years, and institution (Berlin 
versus Tübingen versus all other sites). 
 
Randomisation and masking 
The patients were block-randomised using a randomisation list generated in the 
biostatistical center using a self-written computer program. New patients were 
announced by the local investigators via Fax. In this fax the local investigators 
documented demographic data necessary for stratification and confirmed informed 
consent. A reply fax disclosed the study arm, i.e., whether chemotherapy was to be 
followed by WBRT (A1, B1) or chemotherapy alone (A2, B2) (Figure 1). Treatment 
was not blinded (neither treating physicians, nor patients, nor evaluating physicians) 
as sham radiotherapy was not feasible and evaluating physicians were the same as 
treating physicians. 
 
Study treatment 
After randomisation, all patients were to receive 6 cycles HDMTX (4 g/m2 as a 4 h 
i.v. infusion D1, biweekly) from 1999-2007 and HDMTX plus ifosfamide (1.5 g/m2 as 
a 3 h i.v. infusion D3-5, biweekly) thereafter. This protocol amendment was a result 
of a continuous analysis of response to primary chemotherapy and reflected  the 
increasing awareness of study sites that HDMTX alone might be an insufficient 
primary chemotherapy for PCNSL. HDMTX dose was adjusted to creatinine 
clearance. Dexamethasone, 3 x 8 mg, D1-10, was given to all patients in cycle 1. 
Supportive therapy included intensive i.v. hydration with urine alkalinization, 
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leucovorin 25 mg i.v. every 6 h starting 24 h after start of HDMTX and mesna 400 
mg i.v., given before as well as 4 and 8 h after ifosfamide. Granulocyte colony-
stimulating factor was not routinely given. 
Response was evaluated by MRI or CT as well as CSF evaluation and slit-lamp 
examination in patients with CSF or ocular involvement. CR was defined as a 
complete resolution of contrast-enhancing lesions on MRI or CT and, in the case of 
initial CSF or ocular involvement, a disappearance of lymphoma cells from these 
sites. Central neuroradiology review after HDMTX-based chemotherapy was 
recommended. 
HDMTX was given for 6 cycles even if patients achieved a CR earlier. Patients 
achieving CR received consolidating WBRT with 45 Gy in 1.5 Gy fractions (arm A1) 
or no further treatment (A2). Patients without CR received WBRT (45 Gy, 1.5 Gy 
fractions) (B1) or HD-Ara-C (2 x 3 g/m2/day as a 3 h i.v. infusion D1-2 three-weekly) 
(B2), which then was assumed the second most active drug in PCNSL.21 Stopping 
rules were: the upper 95% confidence limit for CR < 50% or grade 4 toxicity, 
hematotoxicity and alopecia excluded, in more than 10% of patients in at least one 
study arm. 
After the end of study treatment, patients were observed longitudinally with MRI or 
CT, neurologic examination and additional examinations on clinical suspicion every 
3 months for the first year, every 4 months in the second year, every 6 months in the 
third year and yearly thereafter. Treatment-related neurotoxicity was defined as 
progressive neurologic or cognitive impairment as documented in serial clinical 
examinations in the absence of recurrent lymphoma. 
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The primary endpoint was OS. Secondary endpoints were: CR rate with HDMTX-
based chemotherapy, WBRT or HD-Ara-C, PFS, toxicity assessed by WHO 
classification 1996, and delayed neurotoxicity evaluated by clinical examination and 
white matter changes or brain atrophy on MRI or CT. Sequential MMSE data were 
planned to be collected, but were not obtained as scheduled in the majority of the 
patients. 
The study protocol (http://www.neuroonkologie.de/index.php?id=58) was approved 
by the local institutional review boards or ethics committees. All participants gave 
written informed consent. The study was designed by E.T. and M.W., the founding 
chairmen of the G-PCNSL-SG. Study conduction and data assembly were 
coordinated by A.K.. The statistical design was developed by U.M. and P.M.. The 
statistical analysis was performed by P.M.. The manuscript was written by M.W., 
A.K., P.M. and E.T.. Preliminary data have been reported for HLA associations in 
82,22 treatment tolerability in the elderly in 154,23 relapse patterns in 227,24 CSF 
findings in 116,25 and incidence of leptomeningeal dissemination in 282 patients.26 
 
Statistical considerations  
The goal of the trial was to demonstrate that the omission of WBRT from first-line 
treatment does not compromise OS as the primary endpoint. The CR rate on 
HDMTX was assumed to be 40%. A non-inferiority design was chosen with a margin 
of 0.9. Omission of WBRT was defined as non-inferior to WBRT if the lower two-
sided 95% confidence limit of the hazard ratio (HR) of WBRT versus no WBRT was 
not below 0.9. The study was designed to have 60% power to prove non-inferiority of 
omission of WBRT in case of a HR of 1.2 of WBRT versus no WBRT. The sample 
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size required to detect this difference was 151 patients per group. Endpoints were 
measured from the time of randomisation. OS was measured until death, PFS until 
first progression or death. The total number of patients in the primary population (per 
protocol) was 318 (164 no WBRT versus 154 WBRT). We stopped recruitment with 
patient 318 because of the lag from recruitment to the assessment of the PP status. 
Chi-square tests were used to compare proportions. Mann–Whitney tests were used 
to compare quantitative and ordinal variables. Univariate analyses of survival were 
carried out by the Kaplan–Meier method. The evaluation of differences was 
performed with the log-rank test. The Cox proportional-hazards model was used to 
calculate HR and 95% confidence intervals. In addition, analyses were adjusted for 
potential prognostic factors regardless of differences between study arms. Data from 
patients who died without documented PD were defined as events in the PFS 
analysis. A two-sided p value of less than or equal to 0.05 was considered to 
indicate statistical significance. The analyses were carried out using PASW 
statisticals software release 18 (former SPSS). 
 
Registration number 
www.clinicaltrials.gov NCT00153530 
 
Role of the funding source 
The trial was reviewed by the German Cancer Aid, obtained the Certificate of Quality 
(Gütesiegel A), and was subsequently provided partial funding. The German Cancer 
Aid was not involved in the design of the trial or data collection or data interpretation. 
The funding source had no access to the data. ET, AK, PM and MW had full access 
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to the data. The corresponding author had full access to all of the data and the final 
responsibility to submit for publication. 
 
 
Results 
 
Patient characteristics and disposition 
From 1999-2009, 551 patients (median age: 63 years) entered the study in 75 
centers. Fourteen patients did not receive study treatment: 12 because they did not 
meet inclusion criteria (another histologic diagnosis, severe systemic infection or 
pulmonary embolism before chemotherapy, proof of systemic lymphoma 
manifestations) and 2 because they refused to participate. Eleven patients were 
excluded during initial HDMTX-based chemotherapy: 5 because of appearance of 
exclusion criteria (4 with lymphoma in the bone marrow and 1 with psychosis) and 6 
for consent withdrawal. Of the remaining 526 patients, 66 patients died during 
HDMTX-based chemotherapy (see below), 27 dropped out for patient`s or 
physician`s decision, and 22 did not receive a response evaluation. Thus, 411 
patients entered the post-HDMTX phase with a known response status and 
represent the intention-to-treat (ITT) population. Of these, 318 patients were treated 
as randomised and represent the per protocol (PP) population whereas 49 did not 
receive WBRT although randomised into arms A1/B1 and 44 without CR did not 
receive HD-Ara-C after HDMTX-based chemotherapy although randomised into arm 
B2 (Figure 2). During follow-up, 37 of 203 patients allocated to WBRT received 
salvage chemotherapy, 13 salvage radiotherapy, and 12 both. The 25 patients 
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treated with salvage radiotherapy had not received WBRT as randomised and were 
thus not irradiated twice. Of 208 patients allocated to no WBRT, 41 had salvage 
radiotherapy, 23 salvage chemotherapy, and 33 both (for details, see Web-Table 1, 
Webappendix). 
Patient characteristics for the PP and the ITT-minus-PP populations are summarized 
in Table 1. There were no substantial differences for any parameter between the ITT 
and PP populations (data not shown), and, within the PP population, no difference 
for any parameter between arms A1/A2 and B1/B2 (data not shown). Patients in the 
WBRT arm within the PP population were 1.9 years older than patients in the non-
WBRT arm. Ocular involvement was noted in less than 3% of the patients and thus 
less frequently than observed in other studies19 whereas the rate of partial or 
complete resections was high, with almost 30%, possibly reflecting the participation 
of many primary care centers with limited experience in the management of PCNSL. 
Central pathology review was performed in 272 patients, and yielded the diagnoses 
compiled in Web-Table 2 (Webappendix). Given the non-inferiority design of the G-
PCNSL-SG-1 trial, an analysis of the PP population is most conservative, therefore, 
all data reported below concern the PP population if not stated otherwise.  
 
Acute toxicity 
Of 526 patients, 66 (12.5%) died during HDMTX-based chemotherapy The causes 
of death were acute toxicity in 28 (5.3%), lymphoma progression in 24 (4.6%) and 
other reasons in 14 (2.7%) patients (pulmonary embolism in 5, mesenterial 
infarction, cerebral bleeding, brain infarction, cardiac insufficiency and third-degree 
burn in one patient each and unknown in 4). Death from acute toxicity was more 
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frequent on HDMTX plus ifosfamide than on HDMTX alone (64.7% vs. 34.7% of 
deaths) whereas death from tumor progression was more frequent on HDMTX alone 
(42.9 vs. 17.6% of deaths). Mortality from all reasons was higher in patients > 60 
years (56/337, 16.6%) than in younger patients (10/189, 5.3%) (p<0.001). Table 2 
summarizes grade 3-4 hematologic and non-hematologic toxicities during HDMTX-
based chemotherapy. Web-Table 3 (Webappendix) shows that grade 3-4 
hematological toxicity was increased with HDMTX plus ifosfamide compared with 
HDMTX alone. 
 
Response  
The response rates to HDMTX-based chemotherapy are shown in Table 2, those for 
HDMTX alone compared with HDMTX/ifosfamide in Web-Table 4 (Webappendix). 
Central neuroradiology review was obtained for the response to HDMTX-based 
chemotherapy in 285 patients. A divergent assessment was provided in 28 patients 
(9.8%): PRCR 22 patients, CRPR 1 patient, PRPD 3 patients, PDCR 1 
patient, SDPR 1 patient. Central radiological review was performed retrospectively 
and thus had no impact on the treatment decision which was made in the centers 
according to the local radiologic evaluation unless specific advice from the trial 
centers in Berlin and Tübingen was sought. According to local review, 98 patients 
randomised to chemotherapy plus WBRT and 112 patients randomised to 
chemotherapy alone failed to achieve a CR with HDMTX-based primary 
chemotherapy. In the post-HDMTX phase of the trial, 59 of 131 patients (45%) 
achieved a CR with WBRT and 17 of 68 patients (25%) with HD-Ara-C. 
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Survival 
The median follow-up was 31.8 months (range 1-104.7 months) both for the 
population of patients who met the eligibility criteria and received HDMTX-based 
chemotherapy (n=526) and for the PP population. For the PP population the median 
PFS in the chemotherapy+WBRT arms (A1+B1, n=154, 113 events) was 18.3 
months (95% CI 11.6-25) versus 11.9 months (95% CI 7.3-16.5) in the 
chemotherapy alone arms (A2+B2, n=164, 124 events) (p=0.14, HR 0.82, 95% CI 
0.64-1.07) (Figure 3A). The corresponding 2-year PFS rates were 44% and 31% 
(standard errors 0.04 and 0.038). The median OS was 32.4 months (95% CI 25.8-
39) versus 37.1 months (95% CI 27.5-46.7) (p=0.7, HR 1.06, 95%CI 0.8-1.4, 97 
events in 154 patients versus 96 events in 164 patients) (Figure 4A). Thus the 
primary hypothesis was not proven according to the study protocol since the lower 
confidence limit was smaller than 0.9. For comparison, the corresponding PFS and 
OS data for the ITT population are provided in Figures 3 and 4 B,D,F. Sensitivity 
analyses revealed that these results did not differ between the PP and the ITT 
populations. This was true also after stratification for initial tumor response, that is, 
separate analyses for patients with and without initial CR. 
For patients achieving CR with HDMTX-based chemotherapy, the median PFS in 
arm A1 (with WBRT, n=56) was 36.3 months versus 21.5 months in arm A2 (no 
WBRT, n=96) (p=0.038), and the median OS was 38.8 months versus 39.4 months 
(p=0.56) (Figure 3C and 4C). For patients responding to HDMTX-based 
chemotherapy with PR, SD or PD, the median PFS in arm B1 (WBRT, n=98) was 
5.6 months versus 3.0 months in arm B2 (HD-Ara-C, n=68) (p=0.003), and the 
median OS was 24.3 months versus 18.6 months (p=0.10) (Figure 3E and 4E). No 
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significant differences were found for either PFS or OS when patients treated with 
HDMTX were compared to those treated with HDMTX plus ifosfamide (data not 
shown). The median OS for all 526 patients who fulfilled the eligibility criteria was 
21.5 months (95% CI: 17.8-25.1). 
 
Prognostic factors 
Univariately, only KPS and age were prognostic for OS. The median OS for patients 
< 60 years was 41.7 months, compared with 24.1 months in patients > 60 years 
(p<0.001). On multivariate analysis, these both variables, and additionally gender, 
were significant and thus independent risk factors. In the analysis of PFS, KPS and 
gender, but not age, were prognostic. Note that adjustment for these factors did not 
change the treatment effects (Table 3). The MSK prognosis score27, which 
separates patients in three prognostic groups (< 50 years, > 50 years and KPS > 70, 
> 50 years and KPS < 70) was significantly associated with PFS and OS in all 
patient populations (all, PP, ITT, ITT-minus-PP). In the PP population, the median 
PFS in the three groups was 25.07, 15.01 and 9.79 months (HR 1.34, 95% CI 1.11-
1.62) and median OS was 50.69, 32.5 and 19.06 months (HR 1.56, 95% CI 1.26-
1.92). 
 
Neurotoxicity 
Neurotoxicity analyses were limited to CR patients treated per protocol who 
remained in CR > 3 months after completion of therapy because tumor and 
treatment effects on neurological function cannot be distinguished in patients with 
active tumor. Moreover, patients with cognitive impairment or cerebellar dysfunction 
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present at study entry and persisting after study treatment were excluded. Data of 79 
patients, 45 in the radiotherapy arm (median age: 62) and 34 in the chemotherapy 
alone arm (median age: 63), were available for evaluation of clinically defined 
treatment-related neurotoxicity (median follow-up 49.2 months, range 37.8 – 60.5 
months). Of these 79 patients, 53 had achieved CR with HDMTX-based 
chemotherapy alone, 22 with HDMTX-based chemotherapy plus WBRT, and 4 with 
HDMTX-based chemotherapy followed by HD-Ara-C. Clinically defined neurotoxicity 
was found in 22 patients (48.9%) in the WBRT arm and in 9 (26.5%) in the non-
WBRT arms (p=0.054) after a median time of 1.7 and 2.7 years. Delayed 
neurotoxicity on MRI or CT was evaluated in 84 patients (median follow up: 51.4 
months, range 39.8 – 63.1 months) and found in 35 of 49 (71.4%) patients in the 
WBRT arms and in 16 of 35 (45.7%) in the non-WBRT arms (p=0.04). Of these 84 
patients, 56 had achieved CR with HDMTX-based chemotherapy alone, 25 with 
HDMTX-based chemotherapy plus WBRT, and 3 with HDMTX-based chemotherapy 
followed by HD-Ara-C. 
 
 
Discussion 
 
PCNSL has remained a major challenge in Neuro-Oncology for decades. Among the 
unresolved questions are the cell of origin, the lymphoma cell tropism for the brain, 
the low and late incidence of systemic relapse, the peculiar pattern of early response 
and relapse after exposure to steroids or radiotherapy, and the high risk of 
neurocognitive treatment sequelae. 
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The present randomised phase III trial of the German PCNSL Study Group (G-
PCNSL-SG) sought to demonstrate that primary HDMTX-based chemotherapy alone 
is not inferior to primary chemotherapy followed by WBRT in the management of 
newly diagnosed PCNSL. With 75 active institutions, including primary care 
hospitals, our trial reflects the reality of PCNSL management better than oligocentric 
phase II trials where patients are much more selected. Centralized care in highly 
specialized centers may have a positive impact on outcome in PCNSL28 , although 
this was not confirmed in this trial (Webappendix, Section 2). With a median age of 
63 years, 131 of 551 (24%) of patients >70 years, and 65 patients (14.5%) with KPS 
< 40%, there was some negative patient selection, which may explain the relatively 
high mortality rate on therapy and the inferior long-term outcome compared to 
oligocentric phase II trials with a more positively selected patient population. 
G-PCNSL-SG-1 is only the third randomised, the second completed, and by far the 
largest trial ever performed in that disease entity. The first randomised phase II trial 
sought to compare WBRT followed by CHOP (cyclophosphamide, doxorubicin, 
vincristine, prednisone/prednisolone) with WBRT alone, but was closed for poor 
accrual,29 the second showed superior remission rates of HDMTX plus HD-Ara-C 
compared with HDMTX alone.19 In the present study, the primary hypothesis of non-
inferiority of HDMTX-based chemotherapy alone compared with chemotherapy 
followed by WBRT according to the study protocol asking for a lower confidence limit 
less than 0.9 was not proven. However, the lower confidence limit was within the 
widely accepted non-inferiority range on 0.8, and no significant difference in OS 
between the study arms was found. Thus, the omission of WBRT from the primary 
treatment may not compromise survival, neither in patients achieving a CR with 
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HDMTX-based chemotherapy alone nor in those who do not and require alternative 
treatments early in the disease course (Figures 3 and 4). A previous retrospective 
analysis of heterogenously treated patients did not find a survival benefit for WBRT 
in addition to primary chemotherapy either.21 For patients achieving a CR with 
chemotherapy alone, reducing the WBRT dose was reported to compromise survival 
in a small phase II study.30 Yet, others felt that the dose of WBRT can be safely 
reduced in patients achieving CR with primary HDMTX-based 
immunochemotherapy.31 Here, WBRT provided a gain in PFS that may be clinically 
relevant in patients who do not experience relevant toxicity from WBRT (Figure 3). 
Moreover, WBRT was more effective in patients failing to achieve a CR in response 
to HDMTX-based chemotherapy than HD-Ara-C, confirming the importance of 
WBRT for disease control.32 This did not translate into a survival benefit, most 
probably because of the efficacy of other treatments administered at relapse rather 
than enhanced mortality from WBRT. 
Current efforts to improve outcome in PCNSL explore various options, including (1) 
HDMTX-based polychemotherapy with intrathecal chemotherapy,33-35 (2) HDMTX-
based polychemotherapy plus blood-brain barrier disruption36 and (3) HDMTX-based 
polychemotherapy followed by autologous stem cell transplantation with or without 
adjuvant radiotherapy.37-38 A more puristic approach would try to improve on the 
results obtained with HDMTX alone by combining HDMTX with another 
chemotherapeutic drug instead of WBRT, e.g., with HD-Ara-C19 or with ifosfamide as 
done here. Although higher response rates can be obtained with drug combinations, 
it remains uncertain whether this benefit translates into prolonged disease control 
and survival. While the efficacy of chemotherapy in our trial was lower than that of 
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polychemotherapy in some phase II trials,33,37 it remains to be demonstrated that 
polychemotherapy is superior to HDMTX alone in a less selected patient population 
such as the G-PCNSL-SG-1 PP population. In the present study, CR was 
significantly associated with prolonged OS, as previously observed.28 The median 
OS was 39 months in CR patients versus 22 months in non-CR patients in the ITT 
population (p < 0.001). However, the addition of any cytotoxic agent to HDMTX will 
invariably increase toxicity as observed here for ifosfamide (Web-Table 3, 
Webappendix) or previously for HD-Ara-C.19 
The study has several limitations which are partially explained by insufficient 
funding. The upfront randomisation had historical reasons. It was introduced based 
on the experience of a prior study28 in which patients with CR after primary 
chemotherapy often declined to be randomised to WBRT. This might have 
introduced imbalances between arms. However, there were no significant 
differences in age and KPS in the two study arms in the PP population. Moreover, 
no significant differences in OS according to treatment arm were found when all 
patients (n=551), all patients meeting the inclusion criteria (n=526), or the ITT-
minus-PP populations (n=93) were analyzed (data not shown), indicating that the 
outcome in the two study arms in the PP population was not biased by patient 
selection. Further, we do not dismiss the flaw of 60% power from the statistical point 
of view. However, the framework of the clinical setting of PCNSL in the nineties 
needs to be considered. There were very few international studies in the brain tumor 
field at all and it took until 2009 (!) that the first (small) randomised trial in PCNSL 
was concluded and published (19). There is no doubt that we would not plan this trial 
today in a similar way as we did 12 years ago. The frequent protocol violations (ITT 
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patients, n=411 minus PP patients, n=318: n=93), the high rate of patients lost to 
follow-up (10%), the publication of preliminary data from the trial,22-26 and the 
(retrospectively unnecessary) protocol amendment introducing ifosfamide represent 
further limitations. The neurotoxicity analysis suffers from the small sample size and 
selection cannot be ruled out.  
Age and KPS were confirmed as the most important treatment-independent risk 
factors for OS. Although response rates were comparable in patients < versus > 60 
years of age, PFS and OS were inferior in elder patients. Considering the much 
higher toxicity in this population, future studies must focus on reducing toxicity while 
maintaining remission. For younger patients a curative approach, including the 
evaluation of HD chemotherapy with stem cell transplantation, remains the prime 
goal. Although WBRT plays a role in disease control, the lack of a survival benefit 
observed here may justify its omission from first-line treatment in PCNSL. 
 
Research in context 
Systematic review. A formal systematic review was not performed when designing the 
clinical trial. At the end of the 90ies, data on the therapy of PCNSL was scarce with 
some retrospective analyses and only a few small prospective single arm trials. These 
were systematically reanalysed and reevaluated as summarized in the introduction of 
the G-PCNSL-SG-1 study protocol (www.neuroonkologie.de/index.php?id=58) which is 
only available in German language. Single-arm phase II studies had indicated that long-
term disease control can be achieved by applying WBRT after HDMTX-based 
chemotherapy, however, with a high risk of late neurotoxicity, particularly in the elderly. 
In the first trials using chemotherapy alone and postponing WBRT until progression, a 
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similarly long-term control with less late neurotoxicity was suggested. Thus, it appeared 
appropriate to evaluate the role of WBRT in the primary therapy of PCNSL regarding 
both long-term disease control and late neurotoxicity. 
Interpretation. We can no longer recommend the use of WBRT as a standard of care for 
newly diagnosed PCNSL. Clinicians should enrol patients into clinical trials whenever 
possible. Outside clinical trials, clinicians have to weigh the PFS benefit afforded by 
WBRT against the late neurotoxicity of WBRT. 
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Table 1. Patient characteristics. 
 
 PP 
N=318 (%) 
ITT minus PP 
N=93 (%) 
Demographics 
Age (years) 
   Median 
   Range 
   < 60 
   > 60 
 
61 
19-84 
140 (44) 
178 (56) 
 
63 
31-79 
30 (32.3) 
63 (67.7) 
Sex 
   Male 
   Female 
 
183 (57.5) 
135 (42.5) 
 
53 (57) 
40 (43) 
Diagnostic procedure 
Surgery 
   Gross total resection 
   Partial resection 
   Open biopsy 
   Stereotactic biopsy 
CSF cytology 
Vitreal cytology 
 
45 (14.2) 
52 (16.4) 
32 (10.1) 
184 (57.8) 
3 (0.9) 
2 (0.6) 
 
10 (10.8) 
6 (6.5) 
8 (8.6) 
68 (73.1) 
1 (1.1) 
0 
Neuropathological diagnosis 
   Diffuse large cell B cell      
lymphoma 
 
 
273 (85.8) 
 
 
82 (88.2) 
 28
   T-NHL 
   Other B-NHL 
   No specification 
12 (3.8) 
10 (3.1) 
23 (7.2) 
1 (1.1) 
4 (4.3) 
6 (6.5) 
Neuroimaging on diagnosis      
MRI 
   CT 
   No specification 
 
264 (83) 
53 (16.7) 
1 (0.3) 
 
75 (80.6) 
15 (16.1) 
3 (3.2) 
LDH  
   Normal 
   Elevated  
   Not done 
   No specification 
 
128 (40.3) 
58 (18.2) 
17 (5.3) 
115 (36.2) 
 
34 (36.6) 
23 (24.7) 
9 (9.7) 
27 (29.0) 
Karnofsky Performance Score 
   Median/Range 
 
80.0 (30-100) 
 
80.0 (30-100) 
CSF studies / Slit lamp examination 
Lymphoma cells in the CSF 
   No 
   Yes 
   Suspect 
   No specification 
 
158 (49.7) 
26 (8.2) 
9 (2.8) 
125 (39.3) 
 
39 (41.9) 
11 (11.8) 
1 (1.1) 
42 (45.2) 
CSF protein  
   < 60 mg/dl 
   > 60 mg/dl 
 
93 (29.3) 
91 (28.6) 
 
26 (28.0) 
25 (26.9) 
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   No specification 134 (42.1) 42 (45.1) 
Slit lamp examination 
   No 
   Yes  
   No specification 
 
118 (37.1) 
177 (55.7) 
23 (7.2) 
 
23 (24.7) 
58 (62.4) 
12 (12.9) 
Ocular involvement on slit lamp 
   No 
   Yes 
   No specification 
 
165 (51.9) 
9 (2.8) 
144 (45.3) 
 
53 (57.0) 
3 (3.2) 
37 (39.8) 
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Table 2. Response by local assessment and WHO Grade 3-4 toxicity of primary 
HDMTX-based chemotherapy by age.1 
 
 All patients 
n=526 
 
< 60 yrs 
N=189 
 60 yrs 
n=337 
Response (n, %) 
CR 182 (34.6) 72 (38.1) 110 (32.6) 
PR 101 (19.2) 48 (25.4) 53 (15.7) 
SD 24 (4.6) 6 (3.2) 18 (5.3) 
PD 123 (23.4) 48 (25.4) 75 (22.3) 
Died on therapy 66 (12.5) 10 (5.3) 56 (16.6) 
Unknown 30 (5.7) 5 (2.6) 25 (7.4) 
Hematologic toxicity (n, %)1 
Leukopenia, n=470 112 (23.8) 23 (13.9) 89 (29.3) 
Infections, n=475 128 (26.9) 29 (17.7) 99 (31.8) 
Anemia, n=469 65 (13.8) 14 (8.4) 51 (16.8) 
Thrombocytopenia, n=470 54 (11.5) 8 (4.8) 46 (15.1) 
Non-hematologic toxicity (n, %)1 
Transaminase elevation, 
n=458 
85 (18.6) 35 (21.6) 50 (16.9) 
Lung toxicity, n=460 45 (9.8) 10 (6.1) 35 (11.8) 
Stomatitis, n=459 22 (4.8) 3 (1.8) 19 (6.4) 
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Urea/creatinine elevation, 
n=470 
17 (3.6) 4 (2.4) 13 (4.3) 
Impaired consciousness, 
n=457 
36 (7.9) 9 (5.6) 27 (9.1) 
Peripheral neuropathy, 
n=451 
18 (4,0) 3 (1.9) 15 (5.2) 
Vomiting, n=461 10 (2.2) 4 (2.5) 6 (2.0) 
 
1Data provided for (and relative to) all patients with data on toxicity available. 
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Table 3. Univariate and multivariate analyses for PFS and OS. 
Univariate analysis 
(Simple Cox regression model) 
Multivariate analysis 
(Multiple Cox regression model without 
variable selection) 
Covariate 
HR P value 95% CI HR P value 95% CI 
 PFS 
Age1 1.22 0.13 0.95-1.59 1.11 0.46 0.84-1.49 
KPS2 1.09 0.02 1.01-1.18 1.11 0.012 1.02-1.20 
Gender3 0.84 0.19 0.65-1.09 0.73 0.037 0.55-0.98 
Study arm4 0.82 0.14 0.64-1.07 0.82 0.18 0.62-1.09 
HDMTX/Ifo5 0.94 0.74 0.66-1.34 0.82 0.33 0.55-1.22 
 OS 
Age1 1.69 < 0.001 1.26-2.26 1.54 0.008 1.12-2.12 
KPS2 1.16 <0.001 1.07-1.26 1.16 0.001 1.07-1.27 
Gender3 0.82 0.17 0.61-1.09 0.70 0.031 0.51-0.97 
Study arm4 1.06 0.71 0.80-1.40 1.05 0.74 0.77-1.44 
HDMTX/Ifo5 1.05 0.84 0.66-1.65 1.11 0.69 0.68-1.81 
1 HR refers to patients  60 versus patients < 60 years of age 
2 HR refers to 10% decrease of KPS 
3 HR refers to female versus male patients 
4 HR refers to WBRT versus non WBRT 
5 HR ratio refers to HDMTX plus ifosfamide versus HDMTX alone 
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Figure legends 
 
Figure 1. G-PCNSL-SG-1 trial design. 
 
Figure 2. CONSORT chart. 
 
Figure 3. PFS in the PP and ITT populations by treatment arm: A, all PP patients, B, 
all ITT patients; C, A1 (CR, plus WBRT) versus A2 (CR, no WBRT), PP population, 
D, ITT population; E, B1 (CR, plus WBRT) versus B2 (CR, no WBRT), PP 
population, F, ITT population. 
 
Figure 4. OS in the PP and ITT populations by treatment arm: A, all PP patients, B, 
all ITT patients; C, A1 (CR, plus WBRT) versus A2 (CR, no WBRT), PP population, 
D, ITT population ; E, B1 (CR, plus WBRT) versus B2 (CR, no WBRT), PP 
population, F, ITT population. 
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Webappendix 
 
Section 1 
The following centers and investigators participated in the trial by enrolling the indicated numbers of patients: 
Berlin, Charité (Drs. Kiewe, Mannsmann, Sternemann, Vajkoczy, n=66), Tübingen (Drs. Brugger, Herrlinger, 
Küker, Meyermann, Möhle, n=35), Oldenburg (Drs. Klasen, Steder, Temmesfeld, n=34), Bielefeld Gilead (Drs. 
Krümpelmann, Rohden, Tagliazadeh, Weißinger, n=33), Essen (Drs. Dührsen, Fauser, Meusers, Nowrousian, 
Rauhut, Sack, Seeber, n=33), Bremen (Drs. Kaun, Thomssen, n=27), Magdeburg (Drs. Fischer, Königsmann, 
Markmann, Ochel, Pleger, n=20), Mainz (Drs. Huber, Nguyen-Huu, Wölfel, n=20), Rostock (Drs. Freund, 
Lück, n=16), Munich LMU (Drs. Dudel, Straube, n=16), Trier (Drs. Kirchen, Kölbel, Ley, Weber, n=15), 
Stuttgart KH (Drs. Assmann, Schleicher, n=13), Minden (Drs. Busse, Haukamp, Schubert, n=11), Münster (Drs. 
Berdel, Kerkhoff, Liersch, Meesters, Stelljes, n=11), Nürnberg (Drs. Birkmann, Frank, Hofmann, n=11), 
Dessau (Drs. Florschütz, Kellner, Schön, Schwalbe, n=10), Hamburg North (Drs. Aydogan, Wallat, 
Waschewski, n=8), Hildesheim (Drs. Adomeit, Kaiser, n=8), Hamm (Drs. Costantino, Dürk, Hilleke, Melzner, 
Pelz, n=8), Karlsruhe (Drs. Fischer, Kubin, n=8), Munich TU (Drs. Peschel, von Bubnoff, n=8), Lübeck (Drs. 
Fehm, Heide, Niehoff, Wagner, n=7), Mannheim (Drs. Hehlmann, König, La Rosee, Lengfelder, n=7), Stuttgart 
BH (Drs. Hoffmann, n=7), Bamberg (Drs. Hupp, Krauseneck, Thiel, Weber, n=7), Hannover (Drs. Dengler, 
Ganser, Heidenreich, Kofahl-Krause, Peest, Tatagiba, n=6), Homburg (Drs. Held, Ketter, Murawski, 
Pfreundschuh, Steudel, n=6), Saalfeld (Drs. Fenchel, Meeier, n=5), Regensburg BB (Drs. Baumgart, Kreuser, 
Moribundi, Stauder, n=5), Cottbus (Drs. Peter, Rudoph, n=4), Bremerhaven (Drs. Ahrens, Kurtz, Schmeck, 
n=4), Düsseldorf (Drs. Gattermann, Germing, Pape, Schmidt, n=4), Bochum KK (Drs. Engelhard, Haders, n=4), 
Stuttgart MH (Drs. Denzlinger, Walther, Wedekind, Schmid, n=4), Regensburg UK (Drs. Andreesen, Blank, 
Bogdahn, Hau, Herbst, Krause, Moriabadi, n=4), Neubrandenburg (Drs. Bonhoeffer, Grobe, n=3), Göttingen 
(Drs. Hess, Jung, Lehmann, Schmidberger, Strik, Trümper, n=3), Siegen Ev. Jung-Stilling (Dr. Klump, n=3), 
Hagen (Drs. Eimermacher, Haak, Lindemann, von Rethwisch, n=3), Frankfurt UK (Drs. Chow, Hölzer, n=3), 
Kaiserslautern (Drs. Hübner, Link, n=3), Villingen-Schwenningen (Drs. Brugger, Lohmann, n=3), Halle (Dr. 
Rainov, n=2), Berlin VM (Dr. Rühl, n=2), Berlin HH (Drs. Voigt, Zerm, n=2), Brandenburg/Havel (Dr. 
Deckert, n=2), Stralsund (Drs. Gerecke, Lüdtke, n=2), Kiel (Drs. Hartwig, Kneba, Mehdorn, Strege, Vieler, 
n=2), Celle (Drs. Holtz, Marquard, Sauerland, n=2), Marburg (Drs. Kaiser, Neubauer, Wündisch, n=2), Goch 
(Dr. Runde, n=2), Siegen St. Marten (Drs. Gaska, Gassmann, n=2), Stuttgart DK (Drs. Bair, Bichler, Mück, 
Wöhr, n=2), Leipzig (Drs. Harder, Kortmann, n=1), Jena UK (Dr. Adam, n=1), Bad Saarow (Drs. Fuss, 
Schultze, n=1), Hamburg Altona (Dr. Wernecke, n=1), Flensburg (Dr. Saal, n=1), Emden (Dr. Becker, n=1), 
Rotenburg (Drs. Haits, Reinhardt, n=1), Hameln-Pyrmont (Dr. Buhrmann, n=1), Gütersloh (Drs. Depenbusch, 
Gropp, Westheider, n=1), Fulda (Dr. Ulu, n=1), Aachen (Dr. Gehbauer, n=1), Koblenz (Dr. Weide, n=1), Hagen 
(Drs. Ansorge, Souchon, n=1), Munich-Harlaching (Dr. Hentrich, n=1), Munich-Neuperlach (Dr.Schäfer, n=1), 
Erlangen (Drs. Grüner, Sauer, n=1), Passau (Dr. Prügel, n=1), Würzburg (Dr. Goebeler, n=1), and various 
doctors in private practice (n=3). 
 
Section 2 
To analyse the outcome according to center, we divided the centers into two groups containing approximately 50% 
of patients each: those with a total number of < 20 or >20 enrolled patients. There was no significant difference in 
these two patient groups concerning age and KPS. Interestingly, the OS was longer in the first group both for the PP 
(39.06 versus 31.47 months, p=0.059, HR 1.31, 95% CI 0.99-1.74) and ITT population (37.06 versus 31.47 months, 
p=0.06, HR 1.27, 95%CI 0.99-1.63) whereas no differences were found in all patients and in the ITT-minus-PP 
population. PFS was significantly better in “smaller centers”, too: 15.67 versus 13.63 months, p=0.026, HR1.34, 
95%CI 1.03-1.73). The CR rate was reported higher in “small centers” than in “large centers” (47.5% versus 41.2% 
(ITT) and 51.9% versus 43.9% (PP)) whereas total response rate, PD rate and mortality on therapy were not 
different. Thus, small centers did not negatively impact the outcome parameters in this trial. 
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Web-Table 1. Salvage treatments by study arm 
 
 
Salvage treatments Arms A1/B1 (WBRT) 
(n=203) 
Arms A2/B2 (no WBRT) 
(n=208) 
WBRT n=13* n=41 
Chemotherapy n=37 
   n=14 topotecan 
   n=6 CHOP regimen (patients with systemic 
relapse only) 
   n=3 temozolomide 
   n=3 HD-Ara-C 
   n=2 HD-BCNU/thiotepa with autologous 
stem cell transplantation (ASCT) 
   n=9 other (one patient each: HDMTX, 
PCV, bendamustine, ifosfamide, 
topotecan/ifosfamide, Ara-C/etoposide, 
gemcitabine/oxaliplatin, MTX or liposomal 
Ara-C intrathecally for meningeal relapse) 
n=23 
   n=7 topotecan 
   n=4 HDMTX/ifosfamide 
   n=3 HD-BCNU/thiotepa with ASCT 
   n=2 CHOP regimen (patients with systemic 
relapse only) 
   n=7 other (one patient each: ifosfamide, 
idarubicine/dexamethasone/etoposide/Ara-
C/rituximab, temozolomide/rituximab, 
topotecan/BCNU, HD-Ara-C/trofosfamide, 
PCV, intraocular rituximab for ocular relapse) 
WBRT and chemotherapy n=12 
   n=2 HD-Ara-C 
   n=2 topotecan 
   n=8 other (one patient each: HD-Ara-
C/HDMTX, temozolomide/rituximab, 
HDMTX/ifosfamide, procarbazine, HD-
BCNU/thiotepa with ASCT, HDMTX, 
MTX/Ara-C intrathecally for meningeal 
relapse, intraocular MTX for ocular relapse) 
n=33 
   n=6 topotecan 
   n=6 PCV 
   n=6 HD-BCNU/thiotepa with ASCT 
   n=5 temozolomide 
   n=3 CHOP regimen 
   n=3 HDMTX/ifosfamide 
   n=2 HD-Ara-C 
   n=1 HD-Ara-C/thiotepa 
   n=1 unknown 
*The 25 patients treated with salvage radiotherapy had not received WBRT as randomized and were thus not 
irradiated twice. 
 
 
Web-Table 2. Diagnoses on central neuropathology review (n=272).1 
 
 n (%) 
Diffuse large B cell lymphoma 241 (88.6) 
CNS tissue, consistent with diffuse large B cell lymphoma 5 (1.8) 
CNS tissue, probably diffuse large B cell lymphoma 7 (2.6) 
CNS tissue without tumor 7 (2.6) 
Other lymphomas:  
     T-NHL 6 (2.2) 
     Anaplastic large cell lymphoma 2 (0.7) 
     Low-grade B-NHL 2 (0.7) 
     B-NHL with plasmacytoid differentiation 1 (0.4) 
     Anaplastic plasmacytoma, EBV-positive 1 (0.4) 
 
1272 biopsy specimens were available for histopathology review. All tissue samples were analysed by 
conventional stainings, including hematoxylin/eosin, reticulin and Giemsa staining, as well as 
immunohistochemical staining for CD45, CD20, CD3, CD68, Ki-67 (antibody MIB-1) and glial fibrillary acidic 
protein (antibodies from Dakopatts, Hamburg, Germany). In some cases, CD138, bcl-2, bcl-6, mum-1, CD10 
and CD30 antibodies were employed to further characterize individual cases of non-diffuse large B cell 
lymphoma. Classification of tumors followed the current revised WHO classifications for lymphomas and 
central nervous tumors, respectively. 
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Web-Table 3. WHO grade 3-4 toxicity of HDMTX compared with HDMTX plus ifosfamide.1 
 
 
 HDMTX 
n=401 
HDMTX/ifosfamide n=125 
Hematologic (n, %) 
Neutropenia, n=470 43 (11.8) 69 (64.5) 
Infection, n=475 80 (21.9) 48 (44) 
Anemia, n=469 41 (11.3) 24 (22.6) 
Thrombocytopenia, n=470 34 (9.4) 20 (18.5) 
Non-hematologic (n, %) 
Transaminase elevation, n=458 62 (17.5) 23 (22.1) 
Lung toxicity, n=460 30 (8.34) 15 (14.7) 
Stomatitis, n=459 17 (4.8) 5 (4.9) 
Urea/creatinine elevation, n=470 14 (3.9) 3 (2.8) 
Impaired consciousness, n=457 26 (7.3) 10 (9.7) 
Peripheral neuropathy, n=451 15 (4.3) 3 (3.0) 
Vomiting, n=461 7 (2.0) 3 (2.9) 
 
1Data provided for (and relative to) all patients with data on toxicity available. 
 
 
Web-Table 4. Response to HDMTX versus HDMTX plus ifosfamide by age (n=526). 
 
 
 CR (%) PR (%) SD (%) PD (%) Died (%) Unknown (%) 
HDMTX 
All, n=401 
 
130 (32.4) 
 
71 (17.7) 
 
21 (5.2) 
 
104 (25.9) 
 
49 (12.2) 
 
26 (6.5) 
<60, n=149 56 (37.6) 34 (22.8) 5 (3.4) 42 (28.2) 7 (4.7) 5 (3.4) 
>60, n=252 74 (29.4) 37 (14.7) 16 (6.3) 62 (24.6) 42 (16.7) 21 (8.3) 
HDMTX/ifosfamide 
All, n=125 
 
52 (41.6) 
 
30 (24.0) 
 
3 (2.4) 
 
19 (15.2) 
 
17 (13.6) 
 
4 (3.2) 
<60, n=40 16 (40) 14 (35) 1 (2.5) 6 (15) 3 (7.5) 0 
>60, n=85 36 (42.4) 16 (18.8) 2 (2.4) 13 (15.3) 14 (16.5) 4 (4.7) 
 
 
HDMTX-based chemotherapy
CR No CR
B2: HD-Ara-C
Randomization:
A1/B1 versus A2/B2
A1: Consolidating WBRT B1: Rescue WBRT A2: Watch and wait
CR No CR
Figure 1. G-PCNSL-SG-1 trial design
Figure 2. Modified CONSORT flowchart 
       
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 none of those without CR did not receive WBRT in the chemo+WBRT group 
2 
 
Died during follow-up (n=124) 
Lost to follow-up (n=17) 
Randomized to chemotherapy+WBRT 
(n=273) 
Did not receive initial therapy (n=8): 
 -not meeting inclusion criteria (n=7) 
 -refused participation (n=1) 
Started initial therapy (n=265) 
Excluded during treatment (n=5): 
 -not meeting inclusion criteria (n=3) 
 -refused participation (n=2) 
Received initial therapy (n=260) 
Died during follow-up (n=122) 
Lost to follow-up (n=9) 
Randomized to chemotherapy alone (n= 
278) 
Did not receive initial therapy (n=6): 
 -not meeting inclusion criteria (n=5) 
 -refused participation (n=1) 
Started initial therapy (n=272) 
Excluded during treatment (n=6): 
 -not meeting inclusion criteria (n=2) 
 -refused participation (n=4) 
Received initial therapy (n=266) Initial therapy  
(HDMTX-based 
chemotherapy) 
n=526 
Follow-up 
analysis  
Included n=551 
Allocation 
n=411 
Allocated to chemotherapy+WBRT (n=203: 
105 with CR, 98 without CR) 
Did not receive WBRT (n=49 with CR): 
-refused WBRT (n=29) 
-other therapy (n=11) 
-no further therapy (n=9) 
All 98 patients without CR received WBRT 
Allocated to chemotherapy alone (n=208:  
96 with CR, 112 without CR)) 
Did not receive chemotherapy (no-CR patients; 
n=44): 
-other therapy (n=33 WBRT) 
-no further therapy (n=11) 
All 96 patients with CR had no further therapy 
Died during initial therapy (n=34) 
Lost during initial therapy (n=12) 
Response to initial therapy unknown (n=11) 
Died during initial therapy (n=32) 
Lost during initial therapy (n=15) 
Response to initial therapy unknown (n=11) 
Per protocol 
n=318 Received WBRT (n= 154) 
Received HD-Ara-C (no-CR patients) or no 
further therapy (CR patients) (n=164) 
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